NZ576751A - Anti-angiogenic compounds - Google Patents

Anti-angiogenic compounds

Info

Publication number
NZ576751A
NZ576751A NZ576751A NZ57675107A NZ576751A NZ 576751 A NZ576751 A NZ 576751A NZ 576751 A NZ576751 A NZ 576751A NZ 57675107 A NZ57675107 A NZ 57675107A NZ 576751 A NZ576751 A NZ 576751A
Authority
NZ
New Zealand
Prior art keywords
substituted
group
unsubstituted
antibody
seq
Prior art date
Application number
NZ576751A
Other languages
English (en)
Inventor
Curt Bradshaw
Abhijit Bhat
Jing-Yu Lai
Venkata Doppalapudi
Dingguo Liu
Original Assignee
Covx Technologies Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Covx Technologies Ireland Ltd filed Critical Covx Technologies Ireland Ltd
Publication of NZ576751A publication Critical patent/NZ576751A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ576751A 2006-11-10 2007-11-12 Anti-angiogenic compounds NZ576751A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86536006P 2006-11-10 2006-11-10
US93983007P 2007-05-23 2007-05-23
US94532907P 2007-06-20 2007-06-20
PCT/IE2007/000110 WO2008056346A2 (en) 2006-11-10 2007-11-12 Anti-angiogenic compounds

Publications (1)

Publication Number Publication Date
NZ576751A true NZ576751A (en) 2011-10-28

Family

ID=39364902

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ576751A NZ576751A (en) 2006-11-10 2007-11-12 Anti-angiogenic compounds

Country Status (18)

Country Link
US (3) US8288349B2 (enExample)
EP (2) EP2089425B1 (enExample)
JP (2) JP4897050B2 (enExample)
KR (2) KR101309948B1 (enExample)
CN (1) CN101611053B (enExample)
AT (1) ATE520712T1 (enExample)
AU (1) AU2007318912B2 (enExample)
BR (1) BRPI0718591A2 (enExample)
CA (1) CA2669207A1 (enExample)
DK (1) DK2089425T3 (enExample)
IL (1) IL198581A (enExample)
MX (1) MX2009005045A (enExample)
MY (1) MY146985A (enExample)
NO (1) NO20092203L (enExample)
NZ (1) NZ576751A (enExample)
PL (1) PL2089425T3 (enExample)
PT (1) PT2089425E (enExample)
WO (1) WO2008056346A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0718591A2 (pt) * 2006-11-10 2013-12-03 Covx Technologies Ireland Ltd Compostos antiangiogênicos.
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
US8293714B2 (en) 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
WO2010036930A1 (en) * 2008-09-26 2010-04-01 Javad Parvizi Methods and kits for detecting joint infection
SG186451A1 (en) * 2010-07-12 2013-01-30 Covx Technologies Ireland Ltd Multifunctional antibody conjugates
SG190082A1 (en) 2010-11-05 2013-06-28 Covx Technologies Ireland Ltd Anti-diabetic compounds
EP2726088B1 (en) 2011-06-29 2019-01-02 Amgen Inc. Predictive biomarker of survival in the treatment of renal cell carcinoma
SG11201403324TA (en) * 2011-12-20 2014-07-30 Pfizer Improved processes for preparing peptide conjugates and linkers
US20130323234A1 (en) * 2012-01-09 2013-12-05 Covx Technologies Ireland Limited Mutant antibodies and conjugation thereof
WO2013148877A1 (en) 2012-03-28 2013-10-03 Amgen Inc. Dr5 receptor agonist combinations
DK3007717T3 (da) 2013-06-12 2019-01-02 Pharis Biotec Gmbh Peptider med antagonistiske aktiviteter mod naturlig cxcr4
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
PT3057585T (pt) * 2013-10-15 2020-10-21 Seagen Inc Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando
WO2016209972A1 (en) 2015-06-26 2016-12-29 Amgen Inc. Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
EP3433278A4 (en) 2016-03-25 2019-11-06 Seattle Genetics, Inc. METHOD FOR THE PRODUCTION OF PEGYLATED ACTIVE LINKERS AND INTERMEDIATE PRODUCTS THEREOF
SG10201912034UA (en) 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
JP7527787B2 (ja) 2017-03-24 2024-08-05 シージェン インコーポレイテッド グルクロニド薬物－リンカーの調製のためのプロセスおよびその中間体
CA3061467A1 (en) 2017-04-28 2019-10-24 Ajinomoto Co., Inc. Compound having affinity substance to soluble protein, cleavable portionand reactive group, or salt thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5216132A (en) 1990-01-12 1993-06-01 Protein Design Labs, Inc. Soluble t-cell antigen receptor chimeric antigens
ATE155482T1 (de) 1990-04-06 1997-08-15 Jolla Cancer Res Found Verfahren und verbindung zur behandlung von thrombose
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US6080840A (en) 1992-01-17 2000-06-27 Slanetz; Alfred E. Soluble T cell receptors
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5733757A (en) 1995-12-15 1998-03-31 The Scripps Research Institute Aldolase catalytic antibody
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6326176B1 (en) * 1997-12-18 2001-12-04 The Scripps Research Institute Aldol condensations by catalytic antibodies
AU1190101A (en) 1999-09-27 2001-04-30 Regents Of The University Of California, The Engineering antibodies that bind irreversibly
US6294374B1 (en) * 1999-10-08 2001-09-25 The Scripps Research Institute Use of catalytic antibodies for synthesizing epothilone
JP4303105B2 (ja) 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
US20030045477A1 (en) 2001-07-26 2003-03-06 Fortuna Haviv Peptides having antiangiogenic activity
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
KR20040058229A (ko) * 2001-10-22 2004-07-03 더 스크립스 리서치 인스티튜트 항체 표적화 화합물
US6737524B2 (en) * 2002-03-25 2004-05-18 Paul K. Smith Activated polyethylene glycol compounds
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
CA2511910A1 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
EP1773400A2 (en) * 2004-07-08 2007-04-18 Amgen Inc. Therapeutic peptides
CA2580796C (en) * 2004-09-24 2013-03-26 Amgen Inc. Modified fc molecules having peptides inserted in internal loop regions
BRPI0718591A2 (pt) * 2006-11-10 2013-12-03 Covx Technologies Ireland Ltd Compostos antiangiogênicos.

Also Published As

Publication number Publication date
US8912148B2 (en) 2014-12-16
CN101611053B (zh) 2015-06-03
IL198581A (en) 2015-10-29
JP4897050B2 (ja) 2012-03-14
WO2008056346A2 (en) 2008-05-15
PT2089425E (pt) 2011-10-17
WO2008056346B1 (en) 2008-12-04
DK2089425T3 (da) 2011-10-10
US20080166364A1 (en) 2008-07-10
EP2368908A2 (en) 2011-09-28
KR20120043028A (ko) 2012-05-03
JP2012121886A (ja) 2012-06-28
BRPI0718591A2 (pt) 2013-12-03
CN101611053A (zh) 2009-12-23
US8288349B2 (en) 2012-10-16
US20150057431A1 (en) 2015-02-26
CA2669207A1 (en) 2008-05-15
ATE520712T1 (de) 2011-09-15
JP2010509315A (ja) 2010-03-25
AU2007318912B2 (en) 2011-03-03
MY146985A (en) 2012-10-15
MX2009005045A (es) 2009-11-10
EP2089425A2 (en) 2009-08-19
AU2007318912A1 (en) 2008-05-15
PL2089425T3 (pl) 2012-02-29
IL198581A0 (en) 2011-08-01
WO2008056346A3 (en) 2008-10-23
US20120301431A1 (en) 2012-11-29
EP2368908A3 (en) 2011-10-12
EP2089425B1 (en) 2011-08-17
NO20092203L (no) 2009-08-10
KR20090090331A (ko) 2009-08-25
KR101309948B1 (ko) 2013-09-23

Similar Documents

Publication Publication Date Title
AU2007318912B2 (en) Anti-angiogenic compounds
US7521425B2 (en) Anti-angiogenic compounds
AU2009245324B2 (en) Anti-angiogenic compounds
AU2008203641B2 (en) Glucagon-like protein-1 receptor (GLP-1R) agonist compounds
AU2011202645B2 (en) Anti-angiogenic compounds
EP1863910A1 (en) Targeted plasminogen activator fusion proteins as thrombolytic agents
CN101287485A (zh) 抗血管生成化合物
ES2369587T3 (es) Compuestos anti-angiogénicos.
AU2006218437B2 (en) Anti-angiogenic compounds
HK1125290A (en) Anti-angiogenic compounds
HK1134099A (en) Anti-angiogenic compounds
AU2011254001B2 (en) Glucagon-like protein-1 receptor (GLP-1R) agonist compounds
HK1135416A (en) Glucagon-like protein-1 receptor (glp-1r) agonist compounds

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 12 NOV 2020 BY THOMSON REUTERS

Effective date: 20140912

LAPS Patent lapsed